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Ten-year experience with liver
transplantation at Queen Mary
Hospital: retrospective study
Objective. To report the experience with liver transplantation at the Queen Mary
Hospital from 1991 to 2000.
Design. Retrospective study.
Setting. Liver transplant centre of a University teaching hospital, Hong Kong.
Patients. One hundred and forty-eight patients (127 adults and 21 children)
who underwent a total of 155 liver transplants using 75 cadaver grafts (full-size,
67; reduced-size, 5; split, 3) and 80 living donor grafts (left lateral segment, 15;
left lobe, 6; right lobe, 59) from October 1991 to December 2000 were reviewed.
Main outcome measures. Graft and patient survival rate.
Results. The most common disease indications for liver transplantation were
chronic hepatitis B–related liver disease (n=74) in adults and biliary atresia (n=14)
in children. Eighteen patients had hepatocellular carcinoma. Forty-eight (31%)
liver transplants (three ABO-incompatible) were performed in high-urgency
situations for patients requiring intensive care. The proportion of living donor
liver transplants was 47.7% in adults and 73.9% in children. The overall 1-year
and 5-year patient survival rates were 82% and 77%, respectively. The survival
of high-risk recipients, such as those with fulminant hepatic failure (80%), chronic
hepatitis B (81%), or hepatocellular carcinoma (94%), was not inferior to that of
other patients.
Conclusion. Over the last decade, the promotion of (cadaver) organ donation
through public education coupled with innovative techniques in living donor liver
transplantation have enabled a liver transplantation programme to be established
in Hong Kong with gratifying results.
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Introduction
The first liver transplant in Hong Kong was performed at the Queen Mary
Hospital in October 1991. In its initial stages of development, the liver trans-
plantation programme was seriously restricted by a lack of organ donors, lack of
funding, and the prevalence of hepatitis B virus–related end-stage liver diseases.
CME
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The application of this life-saving procedure was limited:
only a small number of operations were performed to the
benefit of a few selected patients. Ironically, patients con-
sidered to be at highest risk for requiring a transplant,
including those with fulminant hepatic failure, high-urgency
status requiring intensive care, hepatitis B–related liver
diseases, and hepatocellular carcinoma (HCC), were
excluded from the programme. Over the last 10 years,
however, various strategies have been adopted that have
ultimately led to wider application of liver transplantation
in Hong Kong. In this study, we review our experience with
liver transplantation at the Queen Mary Hospital.
Subjects and methods
Data on all liver transplantations performed between
October 1991 and December 2000 were reviewed. All
recipients suffered from end-stage liver diseases with widely
recognised indications for liver transplantation,1 such as
spontaneous bacterial peritonitis, hepatic encephalopathy,
hepatorenal syndrome, intractable ascites or hydrothorax,
recurrent variceal bleeding, or failure to thrive. The suit-
ability for liver transplantation was evaluated by a multi-
disciplinary team consisting of surgeons, hepatologists,
paediatricians, anaesthesiologists, respiratory physicians,
cardiologists, and clinical psychologists, and was discussed
at a monthly transplantation meeting before the recipient
was accepted onto the waiting list. High-urgency patients
requiring intensive care because of acute or chronic liver
failure were accepted for emergency transplantation from
1994 onwards. Patients with hepatitis B–related liver dis-
eases were accepted onto the waiting list for liver trans-
plantation (under lamivudine prophylaxis2) from 1995
onwards. Selected patients with HCC of less than 5 cm in
diameter and no more than three tumour nodules3 were
accepted onto the waiting list from 1997 onwards.
During the programme’s 10-year period to date, the
supply of cadaver donor liver grafts improved as a result of
public education and relaxation of the criteria for donor
acceptability. Marginal donors, such as those of advanced
age, or who had adverse in-hospital events, or who had
received inotropes, were frequently used and the decision
for rejecting an organ was based largely on the surgeon’s
visual assessment of the organ at the time of the donor
operation. The only absolute contraindications for donation
were the presence of systemic infection, transmissible
diseases, or malignancy. In addition, agreements were made
to collaborate with transplantation centres in neighbouring
regions, including Singapore and Taiwan, in the sharing of
liver grafts.
To provide a source of organs for paediatric patients,
the techniques of reduced-size liver transplantation4 and
living donor liver transplantation5 were introduced in 1993.
Living donor liver transplantation has been extended to adult
recipients by pioneering surgical innovations using left
lobe grafts from living donors since 1994,6 and right lobe
grafts since 1996.7 The donor selection and technique of
living donor liver transplantation have been described
previously.7-10 In brief, the primary selection criterion was
the donor’s voluntarism, and all potential donors were evalu-
ated by clinical psychologists. The medical evaluation
started with blood test screening for ABO blood group com-
patibility, transmissible diseases, liver function, and fitness
for liver resection. Segmental liver volume was estimated by
computed tomography scan with volumetry11 to determine
whether a left lateral segment, left lobe, or right lobe graft
was appropriate. Hepatic arteriogram was also performed
to evaluate the vascular anatomy. Since 1998, transplants
involving living donors other than first-, second-, and third-
degree relatives or spouses (with legally supporting docu-
mentation as to their status), could only be carried out after
prior approval by the Human Organ Transplant Board.12
At the beginning, immunosuppression consisted of a
triple regimen of cyclosporin, steroid, and azathioprine. Re-
jection episodes that were confirmed by liver biopsy were
treated with steroid pulse therapy and resistant rejections
were treated with orthoclone OKT3 (muromonab CD3) or
conversion to tacrolimus. Since 1997, a double regimen of
tacrolimus and steroid has been adopted. The target trough
level of tacrolimus was set at 15 ng/mL in the first month
and 3-8 ng/mL subsequently, provided graft function
remained normal. The dosage of steroid was reduced pro-
gressively with the aim of eliminating steroid use completely
at 6 months after transplantation. Rejection episodes were
treated with an increase in tacrolimus dosage and additional
steroid pulse therapy when necessary; OKT3 was rarely
used. No patient was lost to follow-up and their status was
updated to 31 March 2001.
Results
A total of 155 liver transplantations, including seven re-
transplants, were performed in 148 patients (127 adults
and 21 children). There were 99 male and 49 female
patients with a median age of 43 years (range, 6 months-68
years). The annual number of transplants increased rapidly
from two in 1991 to 41 in 2000 because of an increase in
both cadaver and living donor operations (Fig). There were
75 cadaver grafts (full-size, 67; reduced-size, 5; split, 3) and
80 living donors grafts (left lateral segment, 15; left lobe,
6; right lobe, 59). All cadaver grafts were harvested from
various Hospital Authority hospitals with the exception
of four from private hospitals (Table 1). One liver graft
from the Queen Elizabeth Hospital was split into two for
two adults, and one split right lobe graft was imported from
Taiwan. The proportion of living donor liver transplants was
47.7% in adults and 73.9% in children. Forty-eight (31%)
transplantations, three involving ABO-incompatible grafts,
were performed in high-urgency situations for patients
requiring intensive care, including 20 who suffered from
fulminant hepatic failure. The most common disease indi-
cation for transplantation was chronic hepatitis B–related
liver diseases (n=74) in adults and biliary atresia (n=14) in
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children (Table 2). Hepatocellular carcinoma was present
in 18 patients (four with incidental tumours detected at
transplantation and 14 with known tumours diagnosed
before transplantation). One patient with polycystic liver
and kidney disease received a combined liver and kidney
transplant.
Overall survival
The overall 1-year and 5-year patient survival rates were
82% and 77%, respectively. The corresponding graft
survival rates were 81% and 72%, respectively. The 5-year
survival rate was 76% for adults and 81% for children.
High-risk recipients
The graft survival rate following 48 emergency transplants
for high-urgency patients was 81% at 1 year and 73% at 5
years. Sixteen (80%) of 20 patients with fulminant hepatic
failure, including one who received an ABO-incompatible
liver graft, survived. The other two ABO-incompatible liver
grafts, however, did not survive: one due to hyperacute
rejection and the other following fungal infection.
Of the 74 patients who received a liver transplant for
chronic hepatitis B–related liver diseases, 81% were alive
at a median follow-up of 21 months (range, 5-69 months).
Two (2.7%) patients had viral breakthrough due to the
emergence of lamivudine-resistant tyrosine-methionine-
aspartate-aspartate (YMDD) mutants. One developed
graft failure at 16 months and was well with normal liver
function at 28 months after re-transplantation using adefovir
and hepatitis B immunoglobulin prophylaxis. The other
patient was treated with adefovir and had normal graft
function at 59 months.
Seventeen (94%) of 18 patients with HCC were alive at
a median follow-up of 16 months (range, 6-70 months)
after transplantation. The only death was caused by
empyema thoracis 1 year after transplantation in a patient
with no evidence of recurrence. One patient developed
recurrence in the form of a solitary pulmonary metastasis,
which was resected at 10 months after transplantation.
Living donor liver transplants
Table 3 shows the relationship to the recipients of the 80
living liver donors. The most common donors were a spouse
for an adult and a parent for a child. The median blood loss
for the donor operation was 500 mL (range, 150-2600 mL)
Fig. Number of liver transplantations performed at the Queen Mary Hospital each year
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Table 1. Source of 75 cadaver donor grafts
Hospital No. of cadaver donor grafts
Queen Elizabeth Hospital 23*
Queen Mary Hospital 22
Prince of Wales Hospital 6
Kwong Wah Hospital 6
Private hospitals 4
United Christian Hospital 3
Caritas Medical Centre 3
Pamela Youde Nethersole Eastern Hospital 2
Princess Margaret Hospital 2
Others 4†
Total 75
* Includes two split-liver grafts from one donor
† One each from Tuen Mun Hospital, Northern District Hospital, Yan Chai
Hospital, and a split right lobe graft from Chang Gung Memorial Hospital,
Kaohsiung, Taiwan
Table 2. Disease indications for 155 liver transplantations
Disease indication No. of liver transplants
Cirrhosis 76 (13)*
hepatitis B 51
hepatitis C 7
alcoholic 6
primary biliary 6
crytogenic 4
secondary biliary 2
Acute-on-chronic hepatitis B 22 (4)
Fulminant hepatic failure 20
Biliary atresia 14
Re-transplantation 7
Wilson’s disease 4
Autoimmune hepatitis 3 (1)
Polycystic liver 4†
Others 5‡
Total 155
* Number of patients with associated hepatocellular carcinoma is indicated in
brackets
† Includes one combined liver and kidney transplant
‡ One each of Criggler-Nijjar syndrome, tyrosinaemia, familial amyloidotic
polyneuropathy, ruptured hepatocellular adenoma, and Alagille syndrome
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and only one donor with preoperative anaemia required
1 unit of homologous packed cell transfusion. The average
hospital stay was 10 days (range, 5-38 days) and the com-
plication rate was 26.3% (Table 4). Three (3.8%) donors
required further surgery, one each for incisional hernia, bile
duct stricture, and small bowel obstruction from an adhe-
sion band. All were well with normal liver function at a
median follow-up of 58 months (range, 3-60 months). The
1-year and 5-year graft survival rates of living donor grafts
were 78% and 76%, respectively, and were comparable to
those of cadaver donor liver grafts.
Discussion
Since the first human liver transplant was performed in
1963, liver transplantation has rapidly evolved from an
experimental procedure to become the most effective
treatment option for almost all non-malignant end-stage liver
diseases and for selected patients with hepatic malignancies.
Continuous developments in organ preservation, immuno-
suppression, surgical technique, anaesthesiology, and inten-
sive care medicine have refined the procedure and improved
the outcome of patients after transplantation. The 1-year
patient survival rate for those transplanted in recent years
averaged 80% to 85%13,14 and quality of life was good.15,16
At the outset, the scarcity of cadaver grafts was the most
important factor limiting the application of liver trans-
plantation in Hong Kong. Moreover, despite the increase in
cadaver liver donors as a result of public education and
maximal use of marginal donors over the last decade, the
donor rate has remained low at less than three per million
population per year. This translates into a very long waiting
time of 18 to 24 months with a mortality rate on the waiting
list of over 40%17 (90% for high-urgency patients9).
The development of innovative techniques in living
donor liver transplantation has widened the applicability
of the operation so that more patients with end-stage liver
disease can benefit from this life-saving procedure. The
use of a liver graft from a living donor provides the unique
opportunity for the patient and his or her family members
to control the timing of the transplant operation together
with the transplant team. The timing of a liver transplant
determines the outcome after transplantation, particularly
in patients with hepatic malignancy18 and high-urgency
status.19 The risk involved to the living donor taking part
is the major concern20 and at least two donor mortalities
have been reported in the literature.21,22 Nonetheless, the
excellent results and the overwhelming survival benefit
for the recipients, together with the safety of the donor
operation in this series, justify the continuous use and
expansion of this technique in Hong Kong. In fact, such
favourable results have prompted an increasing number
of patients and their relatives to request this treatment
option; as a result, the growth in living donor grafts has out-
numbered that of cadaver grafts in recent years. Currently,
living donor liver transplants account for over three
quarters of all liver transplants performed each year at the
Queen Mary Hospital.
Other measures aimed at expanding the donor pool
have had limited success. As expected, regional sharing of
organs23 has a very limited role because most transplant
centres in Asia are short of organs and would not have any
surplus for sharing. Although split-liver transplantation24
offers the attractive concept of transplanting two patients
with one donor liver, the logistical difficulties of mounting
two simultaneous transplants and associated resource con-
straints seriously limit its wider application in Hong Kong
at this time.
When the liver transplantation programme first began,
we adopted strict selection criteria for recipients. This was
particularly important given the severe shortage of organs
that prevailed, and only selected patients who were most
likely to benefit from the procedure were accepted onto the
waiting list. Patients who required urgent liver transplant-
ation for fulminant hepatic failure or other reasons were
usually considered high-risk candidates with poor outcome.
For patients with hepatitis B–related liver diseases or HCC,
the concern was disease recurrence. The strict selection
policy of only transplanting the fittest deprived these high-
risk patients of the benefit of the procedure and severely
restricted its application. With increasing experience,
however, we have progressively extended the indication
for transplantation to include such high-risk patients. Our
results show that with aggressive medical treatment, appro-
priate patient selection, and advances in therapeutic
modalities, the results of liver transplantation in these
patients may not be inferior to those in others. In particular,
the lower viral breakthrough rate and the favourable results
of liver transplantation for patients with chronic hepatitis B
Table 3. Relationship to recipients of 80 living liver donors
Relationship Adults, n=64 Children, n=16
Spouse 26 0
Parent 4 14
Offspring 14 0
Sibling 12 1
Brother-in-law 2 0
Friend 1 1
Others 5* 0
* One each from a nephew, uncle, aunt, son-in-law, and sister-in-law
Table 4. Complications in 80 living liver donors
Complication No. of living liver donors
Wound infection 9
Cholestasis 3
Bile duct stricture 1
Bleeding duodenal ulcer 1
Small bowel obstruction 1
Incisional hernia 1
Transient peroneal nerve palsy 1
Occipital pressure sore 1
Subphrenic collection 1
Urinary tract infection 1
Pleural effusion 1
Total 21
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using lamivudine prophylaxis in our series as compared to
other reports25 contrasts sharply with earlier claims that
Asians with chronic hepatitis B have poorer outcomes
after transplantation.26 We believe, therefore, that chronic
hepatitis B infection, which is the most common cause of
end-stage liver disease in Hong Kong, should no longer be
a contraindication to liver transplantation. For HCC, which
is the second most common cause of cancer death in Hong
Kong, there was only one recurrence at a median follow-up
of 16 months. This is an encouraging observation since
recurrences tend to develop within the first year of trans-
plantation.27 We believe that with proper patient selection,
liver transplantation may offer the best chance of long-
term survival for certain individuals with HCC. In the future,
it is likely that more and more patients with this disease
will request this treatment option, especially as the timing
of the operation can now be controlled with the advent of
living donor liver transplantation.
Conclusion
The results of liver transplantation at the Queen Mary
Hospital, Hong Kong, compare favourably with those
of other well-established liver transplantation centres
around the world. Our liver transplantation programme has
developed over the last decade into an internationally reput-
able one, particularly in living donor liver transplantation.
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